IP Verse

Betapharm Arzneimittel competitive analysis

Latest oppositions filed by Betapharm Arzneimittel

Explore patent oppositions filed by Betapharm Arzneimittel against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Sep 17, 2026
Patent NumberTitleApplicantOpposition Date
EP2396005
Sglt-2 Inhibitor For Treating Type 1 Diabetes Mellitus, Type 2 Diabete Mellitus, Impaired Glucose Tolerance Or HyperglycemiaBOEHRINGER INGELHEIMAug 24, 2026
EP3539540
Pharmaceutical Composition, Methods For Treating And Uses ThereofBOEHRINGER INGELHEIMSep 18, 2025
EP4321157
New Use Of A Combination Of An Angiotensin Receptor Blocker (Arb) With A Neutral Endopeptidase Inhibitor (Nepi)NOVARTISJul 23, 2025
EP2653873
Compositions And Uses For Treating Multiple SclerosisBIOGEN IDEC MAMay 21, 2025
EP3494972
Combinations Of Dolutegravir And Lamivudine For The Treaetment Of Hiv InfectionVIIV HEALTHCARESep 11, 2024
EP3626270
New UseNOVARTISJul 2, 2024
EP3294283
Sacubitril-Valsartan Dosage Regimen For Treating Heart FailureNOVARTISDec 7, 2023
EP2959894
S1P Receptor Modulators For Treating Multiple SclerosisNOVARTISJul 12, 2023
EP3461503
Methods Of Administering Tetrahydrobiopterin, Associated Compositions, And Methods Of MeasuringBIOMARIN PHARMACEUTICALOct 28, 2022
EP2545939
Methods Of Administering Tetrahydrobiopterin, Associated Compositions, And Methods Of MeasuringBIOMARIN PHARMACEUTICALSep 15, 2021

Latest PTAB cases involving Betapharm Arzneimittel

Discover the latest PTAB cases involving Betapharm Arzneimittel, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Betapharm Arzneimittel with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Sep 17, 2026
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
BETAPHARM ARZNEIMITTEL15 - - -
AMGEN14163811
BIOMARIN PHARMACEUTICAL - 2132
NOVARTIS12542 - 21